Darryl Abrams

Darryl Abrams

Auto-generated profile, based on publicly available information

Darryl Abrams

Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2021 in ASAIO Journal
Verified
Journal Article
Closed access
JTJoseph Tonna
Joseph Tonna
DADarryl Abrams
Darryl Abrams
DBDaniel Brodie
Daniel Brodie
JGJohn C. Greenwood
John C. Greenwood
JMJose Alfonso Rubio Mateo-Sidron
Jose Alfonso Rubio Mateo-Sidron
EFEddy Fan
Eddy Fan
Disclaimer: The use of venovenous extracorporeal membrane oxygenation (VV ECMO) in adults has rapidly increased worldwide. This ELSO guideline is intended to be a practical guide to patient selection, initiation, cannulation, management, and weaning of VV ECMO for adult respiratory failure. This is a consensus document which has been updated from the previous version to provide guidance to the clinician.

1 January 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
NQNida Qadir
Nida Qadir
SSSarina Sahetya
Sarina Sahetya
LMLaveena Munshi
Laveena Munshi
CSCharlotte Summers
Charlotte Summers
DADarryl Abrams
Darryl Abrams
EFEddy Fan
Eddy Fan
Background: This document updates previously published Clinical Practice Guidelines for the management of patients with acute respiratory distress syndrome (ARDS), incorporating new evidence addressing the use of corticosteroids, venovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expiratory pressure (PEEP). Methods: We summarized evidence addressing four “PICO questions” (patient, intervention, comparison, and outcome). A multidisciplinary panel with expertise in ARDS used the Grading of Recommendations, Assessment, Development, and Evaluation framework to develop clinical recommendations. Results: We suggest the use of: 1) corticosteroids for patients with ARDS (conditional recommendation, moderate certainty of evidence), 2) venovenous extracorporeal membrane oxygenation in selected patients with severe ARDS (conditional recommendation, low certainty of evidence), 3) neuromuscular blockers in patients with early severe ARDS (conditional recommendation, low certainty of evidence), and 4) higher PEEP without lung recruitment maneuvers as opposed to lower PEEP in patients with moderate to severe ARDS (conditional recommendation, low to moderate certainty), and 5) we recommend against using prolonged lung recruitment maneuvers in patients with moderate to severe ARDS (strong recommendation, moderate certainty). Conclusions: We provide updated evidence-based recommendations for the management of ARDS. Individual patient and illness characteristics should be factored into clinical decision making and implementation of these recommendations while additional evidence is generated from much-needed clinical trials.

15 February 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
DADarryl Abrams
Darryl Abrams
AGA. Reshad Garan
A. Reshad Garan
AAAkram Abdelbary
Akram Abdelbary
MBMatthew Bacchetta
Matthew Bacchetta
RBRobert H. Bartlett
Robert H. Bartlett
T(The Extracorporeal Life Support Organization (ELSO)
The Extracorporeal Life Support Organization (ELSO)

10 September 2021 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
DADarryl Abrams
Darryl Abrams
GMGraeme MacLaren
Graeme MacLaren
RLRoberto Lorusso
Roberto Lorusso
SPSusanna Price
Susanna Price
DYDemetris Yannopoulos
Demetris Yannopoulos
DBDaniel Brodie
Daniel Brodie

1 December 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
PSPratik Sinha
Pratik Sinha
DFDavid Furfaro
David Furfaro
MCMatthew J. Cummings
Matthew J. Cummings
DADarryl Abrams
Darryl Abrams
KDKevin Delucchi
Kevin Delucchi
MOMax R. O’DOnnell
Max R. O’DOnnell
Rationale: Two distinct subphenotypes have been identified in acute respiratory distress syndrome (ARDS), but the presence of subgroups in ARDS associated with coronavirus disease (COVID-19) is unknown. Objectives: To identify clinically relevant, novel subgroups in COVID-19–related ARDS and compare them with previously described ARDS subphenotypes. Methods: Eligible participants were adults with COVID-19 and ARDS at Columbia University Irving Medical Center. Latent class analysis was used to identify subgroups with baseline clinical, respiratory, and laboratory data serving as partitioning variables. A previously developed machine learning model was used to classify patients as the hypoinflammatory and hyperinflammatory subphenotypes. Baseline characteristics and clinical outcomes were compared between subgroups. Heterogeneity of treatment effect for corticosteroid use in subgroups was tested. Measurements and Main Results: From March 2, 2020, to April 30, 2020, 483 patients with COVID-19–related ARDS met study criteria. A two-class latent class analysis model best fit the population (P = 0.0075). Class 2 (23%) had higher proinflammatory markers, troponin, creatinine, and lactate, lower bicarbonate, and lower blood pressure than class 1 (77%). Ninety-day mortality was higher in class 2 versus class 1 (75% vs. 48%; P < 0.0001). Considerable overlap was observed between these subgroups and ARDS subphenotypes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR cycle threshold was associated with mortality in the hypoinflammatory but not the hyperinflammatory phenotype. Heterogeneity of treatment effect to corticosteroids was observed (P = 0.0295), with improved mortality in the hyperinflammatory phenotype and worse mortality in the hypoinflammatory phenotype, with the caveat that corticosteroid treatment was not randomized. Conclusions: We identified two COVID-19–related ARDS subgroups with differential outcomes, similar to previously described ARDS subphenotypes. SARS-CoV-2 PCR cycle threshold had differential value for predicting mortality in the subphenotypes. The subphenotypes had differential treatment responses to corticosteroids.

1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MOMax R. O’dOnnell
Max R. O’dOnnell
BGBeatriz Grinsztejn
Beatriz Grinsztejn
MCMatthew J. Cummings
Matthew J. Cummings
JJJessica E. Justman
Jessica E. Justman
MLMatthew R. Lamb
Matthew R. Lamb
ILIan Lipkin
Ian Lipkin
BACKGROUND. Although convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited. METHODS. We conducted a randomized, double-blind, controlled trial among adults hospitalized with severe and critical COVID-19 at 5 sites in New York City (USA) and Rio de Janeiro (Brazil). Patients were randomized 2:1 to receive a single transfusion of either convalescent plasma or normal control plasma. The primary outcome was clinical status at 28 days following randomization, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population. RESULTS. Of 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to receive normal control plasma. At 28 days, no significant improvement in the clinical scale was observed in participants randomized to convalescent plasma (OR 1.50, 95% confidence interval [CI] 0.83–2.68, P = 0.180). However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22–0.91, P = 0.034). The median titer of anti–SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80–1:320). In a subset of nasopharyngeal swab samples from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. CONCLUSION. In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in day 28 clinical status. However, convalescent plasma was associated with significantly improved survival. A possible explanation is that survivors remained hospitalized at their baseline clinical status. TRIAL REGISTRATION. ClinicalTrials.gov, NCT04359810. FUNDING. Amazon Foundation, Skoll Foundation.